Posts

Ways to create a healthy work-life balance for your employees

Image
  From Dr. Morayo Adisa Staggered employee schedules that consider individual requests and allow for reasonable accommodations. Incentivized subsidized gym/wellness center memberships to promote healthy living and well-being. Mindfulness and respect for boundaries with after-hours texting/communication to maintain a clear distinction between work and personal time.   From Dr. Shawna Flanagan I am a small practice owner with multiple working moms as employees. We are a tight knit group, and everyone does their part to help each other out when things happen with the children. We have employees who stay later so the working moms can pick up their children from school or daycare. When a school play or concert occurs during the day at short notice, everyone chips in and picks up the slack if an employee must slip out of the office for a few hours. Over the years we have had children in the office for short stints when childcare fall through for someone. I think provid...

Advances in Dermatology: 2024 in Review by Cather McKay, MD

Image
  Advances in Dermatology: 2024 in Review  By Cather McKay, MD The past year has been another exciting one in the field of dermatology! New medications and expanded indications give us more options than ever to care for our patients.   Atopic dermatitis and prurigo nodularis More topical options for atopic dermatitis (AD) became available this year with the approval of roflumilast 0.15% cream (Zoryve) in patients aged 6 years and up and tapinarof 1% cream (Vtama) in patients aged 2 years and up. 1,2 Approval of the pan-JAK inhibitor delgocitinib cream for adults with chronic hand eczema is expected based on phase 3 trials. 3 Ruxolitinib cream (Opzelura) is currently approved for ages 12 and up, but has shown safety and efficacy in patients as young as 2 years. 4 IL-13 inhibitor lebrikizumab (Ebglyss) was approved in September for moderate to severe AD in patients 12 years and up who weigh at least 40 kg. 5 Another IL-13 inhibitor, cendakimab, is in develo...